CJC-1295, IPAMORELIN, GHRP-2

Description

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Peptide Blend
CJC-1295 (Mod GRF 1-29), Ipamorelin, and GHRP-2 are all synthetic peptides that are suggested by research teams to potentially stimulate the release of growth hormone. Anecdotal reports suggest that all three peptides appear synergistic when combined as a blend, potentially providing unique peptide action.
CJC-1295 (Mod GRF 1-29) is considered to be an agonist to the receptors for the native Growth Hormone-Releasing Hormone (GHRH). It is an analog of its truncated version called GHRH (1-29) which appears to potentially have the same affinity to the receptors. GHRH 1-29 is potentially the shortest functional sequence of GHRH made up of its initial 29 amino acids. CJC-1295 (Mod GRF 1-29) is a variation that has undergone tetrasubstitution and has been further modified with the addition of a drug affinity complex (DAC) element named N-epsilon-3-maleimidopropionamide. This component may, perhaps, bind to plasma proteins, possibly enhancing the pharmacokinetics of CJC-1295 (Mod GRF 1-29).
Ipamorelin is a pentapeptide that apparently mirrors the effects of the natural hunger hormone, ghrelin. This hormone may activate the ghrelin receptors in the pituitary gland, also known as the Growth Hormone Secretagogue receptors (GHS-R1a) which may trigger the release of growth hormone.
GHRP-2, also known as Growth Hormone Releasing Peptide 2, is a hexapeptide crafted from six distinct amino acids. It is a synthetic peptide analogous to the receptors of the naturally occurring peptide called ghrelin (aka the GHS-R1a receptors). Thus, GHRP-2 and Ipamorelin peptides appear to trigger GHS-R1a and potentially stimulate the release of growth hormone. However, they may also possibly increase food intake due to their reported effect on ghrelin receptors. This is why they are classified by researchers as Growth Hormone Secretagogues (GHSs).